Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Glofitamab con pre-trattamento obinutuzumab per il trattamento del linfoma del sistema nervoso centrale

4 novembre 2026 aggiornato da: City of Hope Medical Center

Uno studio di fase 1b di Glofitamab nel linfoma del SNC

This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma. Glofitamab is a bispecific antibody that can bind to two different antigens (substances that cause the body to make a specific immune response) at the same time. Glofitamab binds to CD20 on lymphoma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Obinutuzumab can also be administered as a pre-treatment to make glofitamab safer and more tolerable. Giving glofitamab with obinutuzumab pre-treatment may be safe, tolerable, and/or effective in treating patients with CNS lymphoma.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVE:

I. To evaluate the safety of glofitamab with obinutuzumab pre-treatment in patients with primary and secondary CNS lymphoma.

SECONDARY OBJECTIVES:

I. To estimate the overall response rate of glofitamab with obinutuzumab pre-treatment in primary and secondary CNS lymphoma.

II. To estimate the complete response rate, duration of response, duration of complete response, progression-free survival, event-free survival, and overall survival of glofitamab with obinutuzumab pre-treatment in primary and secondary CNS lymphoma.

EXPLORATORY OBJECTIVES:

I. To evaluate the degree to which glofitamab crosses the blood brain barrier (BBB) in CNS lymphoma and define biomarkers of response and toxicity to treatment.

II. To assess the utility of tocilizumab to address cytokine release syndrome in CNS lymphoma subjects treated with glofitamab.

III. To assess the utility of corticosteroids to address immune effector cell-associated neurotoxicity syndrome in CNS lymphoma subjects treated with glofitamab.

OUTLINE:

Patients receive obinutuzumab intravenously (IV) on day 1 of cycle 1 and glofitamab IV over 2-4 hours on days 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or positron emission tomography (PET)/CT at screening and cerebrospinal fluid (CSF) and blood sample collection, brain magnetic resonance imaging (MRI) throughout the study. Patients with secondary CNS lymphoma also undergo CT or PET/CT throughout the study. Additionally, patients with baseline CSF involvement, may undergo lumbar puncture throughout the study.

After completion of study treatment, patients are followed up at 30 days and at 3, 6, 9, 12, 18, and 24 months.

Tipo di studio

Interventistico

Iscrizione (Stimato)

20

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Duarte, California, Stati Uniti, 91010
        • Reclutamento
        • City of Hope Medical Center
        • Contatto:
        • Investigatore principale:
          • James Godfrey

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Age: ≥ 18 years

  • Karnofsky performance status (KPS) ≥ 30

  • Histologically confirmed primary or secondary CNS lymphoma. Tumor must be positive for CD20 by immunohistochemistry or flow cytometry on the most recent biopsy. Neuroimaging alone is acceptable in secondary CNS lymphoma cases where all of the following criteria are met: 1) brain MRI findings are consistent with CNS lymphoma, 2) the disease has been histologically documented in other sites, 3) the CNS lesions are concomitant with systemic progression, and 4) a brain biopsy would be unadvised per the treating provider.

    • Cohort 1: Primary CNS lymphoma
    • Cohort 2: Secondary CNS lymphoma
  • Patients must not require urgent treatment initiation due to bulky or rapidly progressing CNS lymphoma that poses risk for impending critical brain failure. This includes > 5 mm of midline shift, radiographic evidence of impending brain herniation, or clinical evidence of significantly increased intracranial pressure such as papilledema

  • Have failed methotrexate-based therapy or are ineligible/refuse high-dose methotrexate treatment (e.g. creatinine clearance [CrCl] < 50 mL/min, effusions, ascites etc)

  • Measurable CNS lymphoma based on gadolinium enhancement of brain or spine MRI and/or positive CSF or intravitreal fluid cytology

  • Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 to prior anti-cancer therapy

  • Alert and able to participate in a full neurological exam

  • Without bone marrow involvement: Absolute neutrophil count (ANC) ≥ 1,000/mm^3

    • NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
  • With bone marrow involvement: ANC ≥ 500/mm^3

    • NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
  • Without bone marrow involvement: Platelets ≥ 75,000/mm^3

    • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
  • With bone marrow involvement: Platelets ≥ 50,000/mm^3

    • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
  • Hemoglobin ≥ 8.0 g/dL

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease, then ≤ 3.0 x ULN is allowed)

  • Aspartate aminotransferase (AST) ≤ 2.5 x ULN

  • Alanine aminotransferase (ALT) ≤ 2.5 x ULN

  • Creatinine clearance of ≥ 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula

  • If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) ≤ 1.5 x ULN

  • If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants

  • If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN

  • If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants

  • Seronegative for HIV antigen/antibody (Ag/Ab) combo

    • Individuals with a positive HIV test at screening are eligible provided, prior to enrollment, they are stable on antiretroviral therapy, have a CD4 count ≥ 200/uL, and have an undetectable viral load
  • Seronegative for active hepatitis B virus (HBV) (surface antigen negative)

    • Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative hepatitis B virus surface antigen [HBsAg]) may be included if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated
  • Seronegative for HCV

    • Participants positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
  • Women of childbearing potential (WOCBP): Negative serum pregnancy test

  • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study and after completion of study treatment as described below separately for males and females

    • Female participants must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 18 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab and 3 months after the final dose of tocilizumab (as applicable), whichever is longer. Women must refrain from donating eggs during this same period

      • Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices
      • Hormonal contraceptive methods must be supplemented by a barrier method
    • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agree to refrain from donating sperm, as defined below:

      • With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 3 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab or 2 months after the last dose of tocilizumab (as applicable), whichever is longer. Male participants must refrain from donating sperm during this same period
    • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.

    • Childbearing potential defined as not being permanently surgically sterilized (men and women) or have not been free from menses for > 1 year (women only). Per this definition, a female participant with tubal ligation is considered to be of childbearing potential

Exclusion Criteria:

  • Contraindication to any of the individual components of glofitamab or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products

  • Prior solid organ transplantation

  • Prior treatment with systemic immunotherapeutic agents, including but not limited to, radio-immuno-conjugates, antibody-drug conjugates, immune/cytokines and monoclonal antibodies (mAbs) (e.g., anti cytotoxic T lymphocyte associated protein 4, anti PD-1, and anti PD-L1) within 2 weeks or five half-lives of the drug, whichever is shorter, prior to day 1 of protocol therapy

  • Prior treatment with glofitamab or other CD20 x CD3 bispecific antibodies

  • Prior use of systemic chemotherapy within 2 weeks of the start of cycle 1

  • Prior treatment with intrathecal chemotherapy within 1 week of the start of cycle 1. Note, in patients with lymphoma restricted to the CSF and no other measurable sites of CNS disease, positive CSF cytology must be documented following the most recent administration of intrathecal chemotherapy

  • Prior treatment with radiotherapy within 2 weeks prior to day 1 of protocol therapy

    • If patients have received radiotherapy within 4 weeks prior to day 1 of protocol therapy, patients must have at least one measurable lesion outside of the radiation field. Patients who have only one measurable lesion that was previously irradiated but subsequently progressed are eligible
  • Prior treatment with chimeric antigen receptor T cell (CAR-T) therapy within 30 days prior to day 1 of protocol therapy

  • Any investigational therapy for the purposes of treating cancer within 21 days prior to the start of cycle 1

  • Corticosteroid use for purposes other than lymphoma symptom control

    • The use of inhaled corticosteroids is permitted

    • The use of mineralocorticoids for management of orthostatic hypotension is permitted.

    • The use of physiologic doses of corticosteroids for management of adrenal insufficiency is permitted.

    • Participants who require lymphoma symptom control during screening may receive steroids in the following manner:

      • Up to 50 mg/day of prednisone or equivalent may be used for lymphoma symptom control during screening
  • History of other malignancy that could affect compliance with the protocol or interpretation of results:

    • Participants with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix at any time prior to the study are eligible
    • Participants with any malignancy appropriately treated with curative intent and the malignancy has been in remission without treatment for > 2 years prior to enrollment are eligible
    • Participants with low-grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to study are eligible
    • If the malignancy is expected to not require any treatment for at least 2 years (this exception should be discussed with the study PI)
  • Unstable cardiac disease as defined by one of the following:

    • Cardiac events such as myocardial infarction (MI) within the past 3 months
    • NYHA (New York Heart Association) heart failure class III-IV
    • Unstable arrhythmias, or unstable angina
  • Recent major surgery within 4 weeks prior to the start of cycle 1, other than for diagnosis

  • Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease with the exception of CNS lymphoma. Exceptions can be granted after discussion with the PI of the study

    • Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurological deficits, as judged by the investigator, are allowed
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)

  • History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion

  • Known or suspected active infection, or reactivation of a latent infection, whether bacterial, viral, fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) within 4 weeks of dosing

  • Active autoimmune disease requiring treatment with immune suppressive medications other than physiologic doses of steroids

    • Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone may be eligible

    • Participants with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study

    • Participants with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible (e.g., participants with psoriatic arthritis are excluded) if all the following conditions are met:

      • Rash covers < 10% of body surface area
      • Disease is well controlled for the last 12 months and requires only low potency topical corticosteroids
  • Clinically significant liver disease, including active viral or other hepatitis or cirrhosis

  • Live, attenuated vaccine within 4 weeks before study treatment infusion on day 1 of cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study. Live vaccines during the study and until participants B cells recover, are prohibited

    • Influenza vaccination should be given during influenza season only. Participants must not receive live, attenuated influenza vaccine at any time during the study treatment period
  • Suspected active or latent tuberculosis (as confirmed by a positive interferon gamma release assay)

  • Participants with a history of progressive multifocal leukoencephalopathy

  • Females only: Pregnant or breastfeeding or intention of becoming pregnant during the study or within 18 months after pretreatment with obinutuzumab or 2 months after the final dose of glofitamab, whichever is longer

  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures

  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (obinutuzumab, glofitamab)

Patients receive obinutuzumab IV on day 1 of cycle 1 and glofitamab IV over 2-4 hours on days 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or PET/CT at screening and CSF and blood sample collection, brain MRI throughout the study. Patients with secondary CNS lymphoma also undergo CT or PET/CT throughout the study. Additionally, patients with baseline CSF involvement, may undergo lumbar puncture throughout the study.

Undergo lumbar puncture

Altri nomi:
  • LP
  • Colpetto spinale

Undergo CT or PET/CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).

Undergo PET/CT

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Given IV

Altri nomi:
  • Gazyva
  • RO5072759
  • GA101
  • Anticorpo monoclonale anti-CD20 R7159
  • GA-101
  • huMAB(CD20)
  • R7159
  • RO 5072759
  • RO-5072759
  • GA 101
  • R-7159

Given IV

Altri nomi:
  • RO7082859
  • Anticorpo monoclonale bispecifico anti-CD20 x anti-CD3 RO7082859
  • RO 7082859
  • Columvi
  • Glofitamab-gxbm
  • RO-7082859

Undergo CSF and blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni

Undergo brain MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of grade 3 or higher non-hematologic toxicity that does not resolve to grade 1 or better within 7 days
Lasso di tempo: During first 2 cycles of treatment (cycle length = 21 days)

For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution.

During first 2 cycles of treatment (cycle length = 21 days)
Incidence of grade 3 or 4 thrombocytopenia associated with grade >= 3 bleeding
Lasso di tempo: During first 2 cycles of treatment (cycle length = 21 days)

For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution.

During first 2 cycles of treatment (cycle length = 21 days)
Incidence of grade 4 neutropenia or grade 4 thrombocytopenia (without clinically significant bleeding) that lasts > 14 days
Lasso di tempo: During first 2 cycles of treatment (cycle length = 21 days)

For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution.

During first 2 cycles of treatment (cycle length = 21 days)
Incidence of grade >= 3 cytokine release syndrome (CRS) not resolving to grade 1 or better within 7 days
Lasso di tempo: During first 2 cycles of treatment (cycle length = 21 days)

For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution.

During first 2 cycles of treatment (cycle length = 21 days)
Incidence of grade 4 CRS
Lasso di tempo: During first 2 cycles of treatment (cycle length = 21 days)

For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution.

During first 2 cycles of treatment (cycle length = 21 days)
Incidence of any emergent grade 3 neurologic toxicity
Lasso di tempo: During first 2 cycles of treatment (cycle length = 21 days)

For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution.

During first 2 cycles of treatment (cycle length = 21 days)
Incidence of emergent grade 4 neurologic toxicity
Lasso di tempo: During first 2 cycles of treatment (cycle length = 21 days)

For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution.

During first 2 cycles of treatment (cycle length = 21 days)
Incidence of any grade 5 toxicity
Lasso di tempo: During first 2 cycles of treatment (cycle length = 21 days)

For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution.

During first 2 cycles of treatment (cycle length = 21 days)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall response rate (ORR)
Lasso di tempo: From start of protocol therapy to disease progression and/or start of other anti-lymphoma therapy, assessed up to 24 months

Will be defined as achieving a best response of complete response (CR) or partial response (PR). Will be tabulated by the response categories. ORR will be estimated as a percentage along with the 95% exact binomial confidence interval.

From start of protocol therapy to disease progression and/or start of other anti-lymphoma therapy, assessed up to 24 months
CR rate
Lasso di tempo: From start of protocol therapy to disease progression and/or start of other anti-lymphoma therapy, assessed up to 24 months

Will be tabulated by the response categories. CR rate will be estimated as a percentage along with the 95% exact binomial confidence interval.

From start of protocol therapy to disease progression and/or start of other anti-lymphoma therapy, assessed up to 24 months
Duration of response (DOR)
Lasso di tempo: From first achievement of PR or CR to time of progression, relapse, or death, whichever is earlier, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median DOR will be estimated when available.

From first achievement of PR or CR to time of progression, relapse, or death, whichever is earlier, assessed up to 24 months
Duration of CR (DOCR)
Lasso di tempo: From first achievement of CR to time of progression, relapse or death, whichever is earlier, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median DOCR will be estimated when available.

From first achievement of CR to time of progression, relapse or death, whichever is earlier, assessed up to 24 months
Progression-free survival (PFS)
Lasso di tempo: From start of protocol treatment to time of progression, relapse, or death due to any cause, whichever occurs earlier, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median PFS will be estimated when available.

From start of protocol treatment to time of progression, relapse, or death due to any cause, whichever occurs earlier, assessed up to 24 months
Event-free survival (EFS)
Lasso di tempo: From the start of protocol treatment to time of progression, relapse, start of any new anti-lymphoma therapy, or death due to any cause, whichever occurs earlier, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median EFS will be estimated when available.

From the start of protocol treatment to time of progression, relapse, start of any new anti-lymphoma therapy, or death due to any cause, whichever occurs earlier, assessed up to 24 months
Overall survival (OS)
Lasso di tempo: From start of protocol treatment to time of death due to any cause, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median OS will be estimated when available.

From start of protocol treatment to time of death due to any cause, assessed up to 24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: James Godfrey, City of Hope Medical Center

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 luglio 2025

Completamento primario (Stimato)

2 gennaio 2029

Completamento dello studio (Stimato)

2 gennaio 2029

Date di iscrizione allo studio

Primo inviato

3 aprile 2025

Primo inviato che soddisfa i criteri di controllo qualità

3 aprile 2025

Primo Inserito (Effettivo)

10 aprile 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 24487
  • P30CA033572 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 24487 (Altro identificatore: City of Hope Medical Center)
  • NCI-2025-02019 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .